A. Azpilikueta

发表

Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy

I. Melero, M. Rodriguez-Ruiz, V. Lang, 2016, European journal of immunology.

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

O. Vasiljeva, M. Belvin, I. Melero, 2021, Proceedings of the National Academy of Sciences.

Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

J. Zapata, I. Melero, M. Rodriguez-Ruiz, 2018, Oncoimmunology.

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2019, Molecular Cancer Therapeutics.

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes

M. Esteller, I. Melero, A. Korman, 2017, Cancer Immunology Research.

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

Lieping Chen, I. Melero, M. Rodriguez-Ruiz, 2022, Journal for ImmunoTherapy of Cancer.

Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

I. Melero, V. Segura, E. Bolaños, 2015, Cancer Immunology Research.

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

J. Miguel, N. Puig, I. Melero, 2015, Leukemia.

Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model

B. Sangro, I. Melero, S. Hervás-Stubbs, 2013, Clinical Cancer Research.

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.

M. Carleton, K. Schalper, I. Melero, 2020, Immunity.

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.

K. Schalper, I. Melero, M. Rodriguez-Ruiz, 2016, Cancer research.

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

I. Melero, J. Pérez-Gracia, A. Arina, 2007, Expert opinion on biological therapy.

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs

J. Zapata, I. Melero, I. Martinez-Forero, 2018, Front. Immunol..

Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.

S. Quezada, I. Melero, M. Rodriguez-Ruiz, 2018, Cancer research.

Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells

J. Prieto, I. Melero, S. Ferrini, 2008, Gene Therapy.

Repurposing the yellow fever vaccine for intratumoral immunotherapy

I. Melero, P. Berraondo, Á. Teijeira, 2019, EMBO molecular medicine.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 (cid:1) / (cid:1) IL2R g null Immunode ﬁ cient Mice

M. Hidalgo, K. Schalper, I. Melero, 2015 .

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

I. Melero, A. Anel, S. Hervás-Stubbs, 2013, Journal of Immunotherapy for Cancer.

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism

I. Melero, M. Rodriguez-Ruiz, J. Pérez-Gracia, 2014, Journal of Immunotherapy for Cancer.

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

J. Prieto, I. Melero, P. Berraondo, 2013, Cancer research.

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

P. Friedl, Lieping Chen, I. Melero, 2015, Proceedings of the National Academy of Sciences.

Cellular cytotoxicity is a form of immunogenic cell death

I. Melero, M. Rodriguez-Ruiz, P. Berraondo, 2020, Journal for ImmunoTherapy of Cancer.

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

J. Prieto, I. Melero, J. Pérez-Gracia, 2007, International journal of cancer.

Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death

I. Melero, P. Berraondo, C. D. de Andrea, 2020, Theranostics.

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

I. Melero, J. Pérez-Gracia, A. Arina, 2008, Clinical Cancer Research.

Intratumoral injection of interferon‐α and systemic delivery of agonist anti‐CD137 monoclonal antibodies synergize for immunotherapy

I. Melero, P. Berraondo, S. Hervás-Stubbs, 2011, International journal of cancer.

In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb

I. Melero, P. Berraondo, A. Arina, 2009, European journal of immunology.

Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells

I. Melero, P. Berraondo, A. Arina, 2007 .

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

M. Hidalgo, K. Schalper, I. Melero, 2015, Cancer research.

Abstract 1691: CD137 (4-1BB) costimulation of CD8 T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

M. Rodriguez-Ruiz, P. Berraondo, M. Sanmamed, 2021, Immunology.

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

María Martínez-López, David Sancho, Maria Jure-Kunkel, 2016, Cancer discovery.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)

I. Melero, J. Pérez-Gracia, P. Berraondo, 2016, Clinical Cancer Research.

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation

I. Melero, D. Sancho, Á. Teijeira, 2018, Cancer Immunology Research.

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes

F. Sánchez‐Madrid, I. Melero, P. Maiso, 2017, Oncoimmunology.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD‐1 and Anti‐CD137 Monoclonal Antibodies

I. Melero, M. Rodriguez-Ruiz, M. Larrayoz, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.

I. Melero, A. Villanueva, X. Matías-Guiu, 2019, Cancer cell.

T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes

J. Zapata, I. Melero, O. Murillo, 2013, The Journal of Immunology.

Polyubiquitin-Dependent Signals from - Monoclonal Antibodies Is Mediated by K63 T Cell Costimulation with Anti-CD137

Ivan Martinez-Forero, Juan M. Zapata, Ignacio Melero, 2013 .

Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels.

I. Melero, S. Valitutti, Á. Teijeira, 2013, The Journal of investigative dermatology.

Intratumoral gene transfer of mRNAs encoding interleukin-12 in combination with decoy-resistant interleukin-18 improves local and systemic antitumor immunity.

I. Melero, P. Berraondo, C. D. de Andrea, 2022, Cancer immunology research.

Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

B. Sangro, I. Melero, P. Berraondo, 2023, Cell reports. Medicine.

Innate Functions of Immunoglobulin M Lessen Liver Gene Transfer with Helper-Dependent Adenovirus

I. Melero, A. Fontanellas, C. Unzu, 2014, PloS one.

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

I. Melero, M. Rodriguez-Ruiz, P. Berraondo, 2023, Oncoimmunology.

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

Roman K. Thomas, I. Melero, M. Larrayoz, 2021, Disease Models & Mechanisms.

Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death

I. Melero, P. Berraondo, C. D. de Andrea, 2020, Theranostics.

CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

J. Zapata, I. Melero, P. Berraondo, 2023, Science advances.

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

I. Melero, P. Berraondo, Á. Teijeira, 2023, Molecular therapy. Nucleic acids.

Abstract 628: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

Lieping Chen, I. Melero, M. Rodriguez-Ruiz, 2022, Cancer Research.

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

M. Hidalgo, K. Schalper, I. Melero, 2015, Cancer research.

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

I. Melero, I. Martinez-Forero, Á. Teijeira, 2015, Proceedings of the National Academy of Sciences.